Moreover, patients with discordant HPV and p16 status had a more ambiguous survival benefit over patients with HPVDNA−/p16− cancer, compared to those with HPVDNA+/p16+ TSCC/BOTSCC. This evidence concerns the gene CDKN2A and cancer.